Patient-Reported Side Effect Bother: Understanding the Value of the Baseline Report
Continued collection of the GP5 item and concomitant work aiming to understand reasons for missingness as well as interpretation is important for evaluating tolerability in cancer trials.
Authors
- Jessica Roydhouse (ORCID: https://orcid.org/0000-0002-8025-5841)
- Anne Zola (ORCID: https://orcid.org/0000-0001-7111-1515)
- Monique Breslin (ORCID: https://orcid.org/0000-0002-8135-3136)
- David F Cella (ORCID: https://orcid.org/0000-0002-9881-4541)
- John Devin Peipert (ORCID: https://orcid.org/0000-0001-5762-7881)
- Melanie Calvert (ORCID: https://orcid.org/0000-0002-1856-837X)
- Gita Thanarajasingam (ORCID: https://orcid.org/0000-0003-2144-5415)
- Ethan Basch (ORCID: https://orcid.org/0000-0003-3813-9318)
- Mary Lou Smith
Institutions
- Northwestern University (US)
- University of North Carolina at Chapel Hill (US)
- University of Tasmania (AU)
- Mayo Clinic in Arizona (US)
- Research Advocacy Network (US)
- NIHR Birmingham Biomedical Research Centre (GB)
- UNC Lineberger Comprehensive Cancer Center
- University of Birmingham (GB)
Publication Details
- Journal
- Patient
- Published
- 2025-08-28
- DOI
- https://doi.org/10.1007/s40271-025-00766-2
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer
- University of Tasmania
- U.S. Food and Drug Administration
- Genentech